Scarica l'app Stockscreener
263.38
0.84%
2.19
Dopo l'orario di chiusura:
263.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$261.19
Aprire:
$269
Volume 24 ore:
11.23M
Relative Volume:
3.77
Capitalizzazione di mercato:
$141.58B
Reddito:
$32.53B
Utile/perdita netta:
$4.23B
Rapporto P/E:
18.72
EPS:
14.07
Flusso di cassa netto:
$6.28B
1 W Prestazione:
-2.68%
1M Prestazione:
-8.51%
6M Prestazione:
-15.01%
1 anno Prestazione:
-4.29%
Intervallo 1D:
$262.21
$269.61
Intervallo di 1 settimana:
$253.30
$272.69
Portata 52W:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Confronta AMGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
263.38 | 141.58B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Inc. stock rises Friday, still underperforms market - MarketWatch
What's Going On With Amgen Stock On Friday? - Benzinga
Amgen (AMGN) Rises Over 3% Amid Novo Nordisk Trial Results - GuruFocus.com
Amgen (NASDAQ:AMGN) Shares Gap UpTime to Buy? - MarketBeat
Principal Financial Group Inc. Purchases 35,785 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Amgen (NASDAQ:AMGN) Reaches New 1-Year LowTime to Sell? - MarketBeat
Amgen stock touches 52-week low at $257.77 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $257.77 amid market shifts - Investing.com Australia
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In? - Insider Monkey
Herceptin Biosimilar Market Future Business Opportunities - openPR
Amgen's SWOT analysis: stock poised for growth amid obesity market potential - Investing.com
Amgen Hit With $50M Infringement Verdict Over Leukemia Drug - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit - Reuters
Amgen Owes Lindis $50 Million Patent Royalty Over Blincyto (1) - Bloomberg Law
Amgen (NASDAQ:AMGN) Stock Rating Lowered by StockNews.com - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
Amgen (AMGN) Stock Moves -0.21%: What You Should Know - Yahoo Finance
Amgen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - Yahoo! Voices
Amgen's SWOT analysis: obesity program drives stock outlook - Investing.com
How Much Would It Take To Earn $100 A Month From Amgen Stock - Yahoo Finance
Amgen's (NASDAQ:AMGN) investors will be pleased with their favorable 34% return over the last three years - Simply Wall St
Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38 - Simply Wall St
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Franklin Resources Inc. - MarketBeat
World Investment Advisors LLC Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares - MarketWatch
Amgen to build $1B North Carolina pharmaceutical plant - Manufacturing Dive
Asset Advisors Investment Management LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Synovus Financial Corp - MarketBeat
Virtu Financial LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ten Years of BLINCYTO® (blinatumomab): Celebrating the History, Impact and Future - Amgen
Wilmington Savings Fund Society FSB Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Tudor Financial Inc. Purchases New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Morse Asset Management Inc Invests $806,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen Inc. (AMGN) Is the Best Safe Stock to Buy According to Analysts? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Invst LLC - MarketBeat
Toronto Dominion Bank Sells 40,188 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amgen plans $1B investment in Holly Springs - Rocky Mount Telegram
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Amgen's Nobel Laureate Network: A Catalyst for Innovation - Marketscreener.com
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
1.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):